Positioning no disclosures inside 60 days, left as found
Options put/call open interest 0.36, read 2026-10-27
Ethical passes the values gate
Price63.75 USD
Fair value60.44
Ethical score95.4/100
RatingFAIR VALUE
Our investment reviews on this name
2026-10-02Read Accumulation57.53+10.8% to today ✓Markup gives way to Accumulation after a 36% rise in 13 weeks
2026-07-02Read Markup42.19+51.1% to today ✓First review on file: Markup
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
Dynatrace, Inc. holds its Accumulation at $63.75. Consolidating, no directional conviction, held for 33 days.
As held on the ledger · 2026-10-27
Phase
Accumulation
Quantitative state
Consolidating, no directional conviction, held for 33 days
Price at the screen
$63.75
Valuation
122.22 trailing · 26.98 forward price to earnings
Values screen
PASS· score 95.4
Beta
0.77
The Workings
Five Screens, Shown in Full
Full pass across all five screens. This security clears the Titan Ethical Standard: its business and its balance sheet both stay inside the lines.
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
0.81%
Below 33%
Interest-bearing debt is just 0.8% of its assets, well under the one-third ceiling: it does not run on borrowed money.
Pass
Interest-bearing cash
11.28%
Below 33%
Cash held in interest-bearing accounts and securities is 11.3% of assets, under the one-third limit.
Pass
Receivables
0.00%
Below 49%
Money owed to the company is 0.0% of assets, under the 49% limit.
Pass
Revenue purity
2.36%
Below 5%
Only 2.4% of revenue comes from non-compliant sources, under the 5% line.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical Read
Why It Clears, in Plain English
Dynatrace, clears all five screens. Its business is in a permissible area, its debt is near-nil, and interest is about 2% of its income, under the ~5% line, so it passes.
Read as at 2026-10-27. It updates when the underlying figures move, and past reads are kept below.
Follow this verdict
Get an email when DT's ethical verdict changes
Today DT passes the screen. If new figures move it to a fail, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
What the Numbers Say It Is Worth
The Fair Value Range
Our analysis reads FAIR VALUE: it trades above our $60.44 fair value estimate, weak competitive moat, 16.20% revenue growth.
Fair value range in USD, drawn from the 2026-10-27 screen. The gold marker is the market price at the same screen. The price runs 1.1% above the base estimate.
Third-party analyst targets: 34 covering, consensus Buy. The average target sits −3% from the screen price.
Reading the gap · Our model and the Street both land near the screened price: fairly valued, with no strong edge either way.
Price History & Projections
Where it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2026-10-27 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Watching every click in the digital maze
Picture a control room tracking every tap and glitch across a global app. That is the daily work at Dynatrace, where revenue still climbs 19 percent a year even as the software market slows. At 44.41 dollars the shares sit 18 percent below our fair value of 52.40, and the business clears our ethical screen without issue.
The case rests on steady top-line growth and a forward multiple of 19.6 times earnings that looks reasonable next to the expansion rate. Consensus from 33 analysts points to a 46-dollar target, close enough to current levels that the stock is not screaming cheap or rich.
Yet the moat is weak, return on equity runs only 6 percent, and profit margins sit at 8 percent. Those thin returns leave little room for error if growth cools or competition intensifies. Analysis, not advice.
The risks · The main risks here are ordinary market swings and the chance our fair-value read proves too optimistic.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
DT trades on the NYSE. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-10-28Accumulation$61.11+0.0%Entry 10
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with near-perfect ethical score. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 46% above its long-term trend line with momentum reading bullish. Over the past year the shares are down 25%. Our forward projection puts the odds of a 10% gain over the next month near 19%. The street (33 analysts) rates it buy, with a mean price target of $44. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-27Accumulation$61.11+0.0%Entry 9
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with near-perfect ethical score. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 46% above its long-term trend line with momentum reading bullish. Over the past year the shares are down 25%. Our forward projection puts the odds of a 10% gain over the next month near 19%. The street (33 analysts) rates it buy, with a mean price target of $44. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-21Accumulation$61.11-3.8%Entry 8
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 3.8% since our last review. Ethical screening: PASS with near-perfect ethical score. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it A, carrying a low risk profile. Technically it is holding around 41% above its long-term trend line with momentum reading bullish. Over the past year the shares are down 25%. Our forward projection puts the odds of a 10% gain over the next month near 19%. The street (33 analysts) rates it buy, with a mean price target of $44.
2026-10-14Accumulation$63.50+10.4%Entry 7
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 10.4% since our last review. Ethical screening: PASS with near-perfect ethical score. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it A, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 25%. Our forward projection puts the odds of a 10% gain over the next month near 19%. The street (33 analysts) rates it buy, with a mean price target of $44.
The framework has shifted from markup to accumulation since the last review. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 17.3% since our last review. Ethical screening: PASS with near-perfect ethical score. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 25%. Our forward projection puts the odds of a 10% gain over the next month near 19%. The street (33 analysts) rates it buy, with a mean price target of $44. Since the last review it its composite score eased; dropped out of the Tech 100.
2026-08-27Markup$49.05+10.4%Entry 5
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 10.4% since our last review. Ethical screening: PASS with near-perfect ethical score. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 25%. Our forward projection puts the odds of a 10% gain over the next month near 19%. The street (33 analysts) rates it buy, with a mean price target of $44.
2026-07-26Markup$44.41+5.3%Entry 4
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 5.3% since our last review. Ethical screening: PASS with near-perfect ethical score. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 25%. Our forward projection puts the odds of a 10% gain over the next month near 19%. The street (33 analysts) rates it buy, with a mean price target of $44.
2026-07-18Markup$42.19+0.0%Entry 3
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with near-perfect ethical score. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 25%. Our forward projection puts the odds of a 10% gain over the next month near 19%. The street (33 analysts) rates it buy, with a mean price target of $44.
2026-07-03Markup$42.19+0.0%Entry 2
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with near-perfect ethical score (95). The risk-adjusted return profile shows modest positive risk-adjusted returns.
2026-07-02Markup$42.19Entry 1
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Ethical screening: PASS with near-perfect ethical score (95). The risk-adjusted return profile shows modest positive risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
